- Benuvia Operations, LLC has signed a research and manufacturing agreement with an Ivy League university to supply pharmaceutical-grade DMT fumarate.
- The psychedelic API will support the university’s research and development activities in areas related to psychological conditions.
Benuvia Operations, LLC (Benuvia), a global contract development and manufacturing organisation, has entered into a research and manufacturing agreement with an Ivy League research university. Under the agreement, Benuvia will supply pharmaceutical-grade DMT fumarate to support the university’s research and development programmes.
DMT fumarate is the fumarate salt form of N,N-dimethyltryptamine, a naturally occurring psychedelic compound being investigated for potential therapeutic applications in conditions such as depression, anxiety, PTSD, and addiction. The company stated that the compound’s psychoactive effects stem from its activity on serotonin receptors, including 5-HT2A.
“We are dedicated to advancing research in psychedelic therapy and are excited to begin this new collaboration,” noting the growing interest in psychedelic approaches to address unmet patient needs.
Terry Novak, chief executive officer of Benuvia
Benuvia operates an FDA-audited and DEA-registered facility in Round Rock, Texas, providing drug substance and drug product manufacturing, analytical development, stability programmes, and regulatory support for controlled substances. The company said its cGMP-certified processes support the production of synthetic cannabinoids and psychedelics for research and clinical use.
